IL7R and multiple sclerosis: The anti-IL-7Rα monoclonal antibody PF-06342674 (RN168) developed from Pfizer has been tested in phase 1b in patients with multiple sclerosis (NCT02045732 ClinicalTrials.gov identifier) with the primary outcome to evaluate adverse side effects and pharmacokinetic–pharmacodynamic properties.